| Sep 11 |
Dupixent succeeds in chronic hives study, giving Sanofi, Regeneron a chance to rebound
|
| Sep 11 |
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
|
| Sep 11 |
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
|
| Sep 9 |
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
|
| Sep 9 |
Update: RBC Raises Price Target on Regeneron Pharmaceuticals to $1,282 From $1,250, Keeps Outperform Rating
|
| Sep 9 |
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
|
| Sep 8 |
Regeneron Pharmaceuticals, Inc. (REGN): The Best Biotech Stock According to Hedge Funds?
|
| Sep 5 |
Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 2024 Healthcare Conference (Transcript)
|
| Sep 5 |
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
|
| Sep 5 |
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
|
